Drug Profile

Research programme: viral vaccines - Gylden Pharma

Latest Information Update: 22 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Emergex Vaccines
Developer Gylden Pharma
Class COVID-19 vaccines; Synthetic vaccines; Viral vaccines
Mechanism of Action T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported COVID 2019 infections

Most Recent Events

17 Oct 2024 Emergex Vaccines is now called Gylden Pharma
28 May 2024 No recent reports of development identified for research development in COVID-2019-infections(Prevention) in United Kingdom (Parenteral)
05 Oct 2023 Emergex enters into collaboration agreement with Vaccine Industrial Company advancing Emergex’s novel T cell-priming immune candidates against infectious diseases

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com